Healthcare provider profile · identity verified

Jane Ostlie, MD

Family Practice · MAYVILLE, ND · NPI 1063672749

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	443	86
Atorvastatin Calcium	Atorvastatin Calcium	367	87
Amlodipine Besylate	Amlodipine Besylate	353	78
Losartan Potassium	Losartan Potassium	304	68
Omeprazole	Omeprazole	259	59
Metoprolol Succinate	Metoprolol Succinate	255	59
Hydrochlorothiazide	Hydrochlorothiazide	247	60
Lisinopril	Lisinopril	230	55
Furosemide	Furosemide	226	54
Rosuvastatin Calcium	Rosuvastatin Calcium	216	48
Gabapentin	Gabapentin	187	47
Simvastatin	Simvastatin	185	43
Sertraline Hcl	Sertraline Hcl	153	30
Metformin Hcl Er	Metformin Hcl	151	33
Potassium Chloride	Potassium Chloride	140	35
Eliquis	Apixaban	132	19
Alendronate Sodium	Alendronate Sodium	115	28
Glipizide Er	Glipizide	99	23
Lorazepam	Lorazepam	91	27
Metformin Hcl	Metformin Hcl	83	23
Duloxetine Hcl	Duloxetine Hcl	82	16
Prednisone	Prednisone	79	36
Mirtazapine	Mirtazapine	77	17
Citalopram Hbr	Citalopram Hydrobromide	72	15
Pantoprazole Sodium	Pantoprazole Sodium	71	19
Metoprolol Tartrate	Metoprolol Tartrate	68	14
Clonazepam	Clonazepam	60	suppressed
Ozempic	Semaglutide	59	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	58	21
Tamsulosin Hcl	Tamsulosin Hcl	58	14
Tramadol Hcl	Tramadol Hcl	57	25
Trazodone Hcl	Trazodone Hcl	57	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	56	13
Allopurinol	Allopurinol	51	11
Oxybutynin Chloride Er	Oxybutynin Chloride	49	15
Bupropion Xl	Bupropion Hcl	48	12
Pravastatin Sodium	Pravastatin Sodium	48	13
Carvedilol	Carvedilol	47	suppressed
Montelukast Sodium	Montelukast Sodium	47	suppressed
Myrbetriq	Mirabegron	47	suppressed
Pregabalin	Pregabalin	47	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	46	13
Albuterol Sulfate Hfa	Albuterol Sulfate	45	23
Donepezil Hcl	Donepezil Hcl	44	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	suppressed
Klor-Con M20	Potassium Chloride	42	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	41	suppressed
Propranolol Hcl Er	Propranolol Hcl	40	suppressed
Warfarin Sodium	Warfarin Sodium	38	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	37	suppressed
Valsartan	Valsartan	37	suppressed
Xarelto	Rivaroxaban	36	suppressed
Clopidogrel	Clopidogrel Bisulfate	34	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	33	suppressed
Jardiance	Empagliflozin	33	suppressed
Oxycodone Hcl	Oxycodone Hcl	32	11
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Fluticasone Propionate	Fluticasone Propionate	31	12
Meloxicam	Meloxicam	31	suppressed
Synthroid	Levothyroxine Sodium	31	suppressed
Humalog Kwikpen U-100	Insulin Lispro	30	suppressed
Novolog Flexpen	Insulin Aspart	30	suppressed
Paroxetine Hcl	Paroxetine Hcl	30	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	30	22
Cephalexin	Cephalexin	29	18
Ezetimibe	Ezetimibe	28	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	28	23
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	27	suppressed
Digoxin	Digoxin	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Tresiba Flextouch U-100	Insulin Degludec	25	suppressed
Atenolol	Atenolol	24	suppressed
Celecoxib	Celecoxib	24	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	24	suppressed
Potassium Citrate Er	Potassium Citrate	24	suppressed
Azithromycin	Azithromycin	23	20
Creon	Lipase/Protease/Amylase	23	suppressed
Verapamil Er	Verapamil Hcl	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Trulicity	Dulaglutide	22	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	21	19
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Arformoterol Tartrate	Arformoterol Tartrate	20	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Budesonide	Budesonide	18	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Finasteride	Finasteride	17	suppressed
Easy Touch Safety Pen Needle	Pen Needle, Diabetic, Safety	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Mounjaro	Tirzepatide	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	13
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Topiramate	Topiramate	16	suppressed
Amoxicillin	Amoxicillin	15	14
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Cefdinir	Cefdinir	14	13
Gemfibrozil	Gemfibrozil	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Estradiol	Estradiol	11	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error